Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety of tenofovir alafenamide (TAF) in patients with a history of tubulopathy on tenofovir disoproxil fumarate (TDF)

Next Previous
Trial Profile

Safety of tenofovir alafenamide (TAF) in patients with a history of tubulopathy on tenofovir disoproxil fumarate (TDF)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs Emtricitabine/tenofovir alafenamide (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms FANCONI-TAF (FANTA) study

    • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 12 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top